

Abstract (Basic): EP 581353 A

New monoclonal antibodies to HIV-1 react with HIV-1 gp120 glycoprotein variants contg. the amino acids Asn-88, Lys-117, Asn-262 and Tyr-435 but exhibit at least 50% reduced reaction with gp120 variants in which one or more of these amino acids have been deleted or mutated.

Also claimed are (1) anti-idiotypic antibodies directed against the monoclonal antibodies, and (unspecified) structures based on such anti-idiotypic antibodies; (2) cell lines producing human or animal monoclonal antibodies as defined above; and (3) nucleotide sequences encoding an amino acid sequence of an antibody to HIV-1, comprising at least 15 consecutive nucleotides from any of six defined sequences given in the specification.

USE - The monoclonal antibodies are useful for passive immunotherapy. The anti-idiotypic antibodies are useful for vaccine prodn.

Dwg. 0/8